ClinicalTrials.gg
Status unknownNCT02483494ALTRAUpdated Aug 4, 2017

Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions

An interventional study of APN-led Telemedicine in Acute Myocardial Infarction and Acute Coronary Syndrome, sponsored by National University Heart Centre, Singapore. Status unknown at 1 site in Singapore. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-08-04.

Sponsored by National University Heart Centre, Singapore · Not applicable, Interventional, and Health services research

How we know

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Acute Coronary Syndrome with a site in Singapore — 2 open to participants now, 3 under way, 1 of them phase 3. Acute Coronary Syndrome · Singapore.

Planned enrollment
10th of 16
300 · median 1,718
Started
2015
with 1 other
No phase
8 of 18
1 open now
Registered
8th of 18
by date
Lead sponsor
3 of 18
National University Heart Centre, Singapore

Among the 18 studies in Acute Coronary Syndrome with a site in Singapore, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 with no phase, and was the 8th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 18 studies in Acute Coronary Syndrome with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Acute Coronary Syndrome with a site in Singapore, or all of them as a file.
02

Study summary

Aim. To develop and examine the effectiveness of an APN-led telehealth rehabilitative programme as a transitional nursing therapeutic on readmission rates and health related outcomes amongst patients with Acute Myocardial Infarction (AMI) post discharge.

Design. Randomized controlled trial with repeated measures.

Methodology. A consecutive sampling of 172 patients with AMI will be recruited from a tertiary hospital in Singapore. Participants will be randomised into two groups. The experimental group (ALTRA) will receive APN-led telehealth rehabilitative programme upon discharge in addition to standard care. The control group will receive only standard follow-up care.

Read the detailed description

Ischaemic heart disease is the third leading cause both for death and illness for hospitalisation in Singapore. Epidemiological data shows that the incidence of acute myocardial infarction (AMI) stands around 7000 plus in Singapore. In United States, nearly 20% of patients with AMI are readmitted within 30 days of discharge causing the healthcare system a huge financial burden. These readmissions have been shown to be associated with lower patient satisfaction and less inefficient healthcare.

Cardiac rehabilitation has been proven to be an effective strategy in improving quality of life and reducing readmission. However, this structured programme which comprise of clinical review, education and exercise, has poor uptake rate for varied reasons. It is important that newer strategies are being explored and developed to cater to the changing needs of the patient population. One of which is to utilize telemedicine with combination of Advanced Practice Nurse delivering the care remotely.

This is a substudy of IMMACULATE STUDY (NCT02468349) where more details can be found.

03

Conditions studied

  • Acute Myocardial Infarction
  • Acute Coronary Syndrome

Keywords

  • Telemedicine
  • Advanced Practice Nurse
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Typical history of ischemic chest pain or angina equivalent symptoms (e.g. acute onset dyspnea)> 30 minutes
  • Undergone PCI for index event
  • NT-Pro-BNP ≥1000 ng/L
  • Cinically diagnosed AMI at high risk of ventricular remodeling (STEMI or NSTEMI):

(Anterior or large inferior STEMI)

  • changes>0.1mV ST segment elevation in two or more contiguous limb leads or precordial leads or
  • Presence of pathological Q waves in two or more contiguous limb leads or precordial leads.
  • Typical rise or fall of cardiac enzymes (cardiac troponin value exceeding the 99th percentile).
  • Angiographic findings of proximal/mid LAD, proximal LCX or RCA occlusion for STEMI.

(Or NSTEMI with)

  • Typical rise or fall of cardiac enzymes (cTn value exceeding the 99th percentile).
  • Peak cTnI should be >10ug/L, TnT-hs>250 ng/L or CK-MB >80 IU/L
  • (echocardiography) ≤ 40% or Kilip class ≥2

Exclusion criteria

Exclusion Criteria:

  • to ticagrelor, aspirin or any
  • Active pathological bleeding
  • History of intracranial haemorrhage
  • Infection within 6 weeks preceding the primary angioplasty, inflammatory disorders, Hepatitis, , disease or on therapy
  • Women of , known to be pregnant, breast-feeding, or intend to become pregnant during the study period.
  • History of non-ischaemic cardiomyopathy or
  • History of significant valvular heart disease (moderate or severe MS, MR, AS, AR, TR)
  • Planned CABG within the next 6 weeks
  • Cardiogenic shock unable to be weaned off inotropes or IABP
  • Asthma or any other to beta-blockers
  • Arrhythmias precluding proper CMR image acquisition, including atrial fibrillation and frequent atrial or ventricular ectopy of > 1 in 5 intrinsic complexes
  • Contraindications to cardiac magnetic resonance imaging including claustrophobia, pacemaker or ICD implantation, mechanical valve or other metallic implants
  • Significant liver impairment
  • Renal impairment (\<45 ml min -1), end stage renal failure on renal replacement therapy
  • Anaemia (\<10 g/dL)
  • Psychosocial barriers to telemedicine adoption (screening for education level, dementia, substance abuse and other psychological disorders)
  • Participants who cannot be followed up
  • Participants not able or willing to consent for study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    APN-led Telemedicine

    Participants will receive APN-led Telemedicine in addition to usual care.

    Other: APN-led Telemedicine

  • No intervention
    Usual care

    Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.

Interventions

  • OtherAPN-led Telemedicine

    Allocation to experimental or Usual care is 1:1. The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention.

06

What researchers measure

Primary outcomes

  1. Readmissions Days

    Cardiac and non-cardiac causes Readmission days per 1000 follow up days will be calculated using the total number of sample in that arm x follow days (i.e. 30 days in this instance) as the denominator. (Please refer to references attached)

    Time frame: 30 days

Secondary outcomes

  1. Readmissions Days Per 1000 follow up days

    Cardiac and non-cardiac causes

    Time frame: 6 months

  2. ED visits or unplanned self-reported doctor visits

    Cardiac and non-cardiac causes

    Time frame: 6 months

  3. Cardiac Self-Efficacy Scale

    Health Related Outcomes

    Time frame: 6 months

  4. Myocardial Infarction Dimension Assessment Scale

    Health Related Outcomes

    Time frame: 6 months

  5. EuroQoL

    Health Related Outcomes

    Time frame: 6 months

  6. Hospital Anxiety and Depression Scale

    Health Related Outcomes

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Young W, Rewa G, Goodman SG, Jaglal SB, Cash L, Lefkowitz C, Coyte PC. Evaluation of a community-based inner-city disease management program for postmyocardial infarction patients: a randomized controlled trial. CMAJ. 2003 Oct 28;169(9):905-10. PubMed 14581307 ↗
  • Koh KW, Wang W, Richards AM, Chan MY, Cheng KK. Effectiveness of advanced practice nurse-led telehealth on readmissions and health-related outcomes among patients with post-acute myocardial infarction: ALTRA Study Protocol. J Adv Nurs. 2016 Jun;72(6):1357-67. doi: 10.1111/jan.12933. Epub 2016 Feb 25. PubMed 26915719 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Jun 2018, 35 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 35 months is close to that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2015
First posted
Jun 29, 2015
StartActual
Jul 8, 2015
Primary completionEst.
Jun 30, 2018
CompletionEst.
Jun 30, 2018
Last update
Aug 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02483494
Lead sponsor
National University Heart Centre, Singapore
Responsible party
Karen Koh (Assistant Director of Nursing, National University Heart Centre, Singapore) — Principal investigator
First posted
Jun 29, 2015
Start date
Jul 8, 2015
Primary completion
Jun 30, 2018 (estimated)
Completion
Jun 30, 2018 (estimated)
Last update
Aug 4, 2017

Study contacts

Karen Koh
Contact
karen_wl_koh@nuhs.edu.sg
+65 6772 6884
Sock Cheng Poh
Contact
sock_cheng_poh@nuhs.edu.sg
+65 9772 0495
Karen Koh
principal investigator · National University Heart Centre, Singapore
A Mark Richards
study chair · National University Heart Centre, Singapore
Mark Chan
principal investigator · National University Heart Centre, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion